JP2010536929A5 - - Google Patents

Download PDF

Info

Publication number
JP2010536929A5
JP2010536929A5 JP2010522361A JP2010522361A JP2010536929A5 JP 2010536929 A5 JP2010536929 A5 JP 2010536929A5 JP 2010522361 A JP2010522361 A JP 2010522361A JP 2010522361 A JP2010522361 A JP 2010522361A JP 2010536929 A5 JP2010536929 A5 JP 2010536929A5
Authority
JP
Japan
Prior art keywords
eur
ingredients
adjusted
composition
value
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010522361A
Other languages
English (en)
Japanese (ja)
Other versions
JP5570988B2 (ja
JP2010536929A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2008/061232 external-priority patent/WO2009027437A1/en
Publication of JP2010536929A publication Critical patent/JP2010536929A/ja
Publication of JP2010536929A5 publication Critical patent/JP2010536929A5/ja
Application granted granted Critical
Publication of JP5570988B2 publication Critical patent/JP5570988B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010522361A 2007-08-27 2008-08-27 G−csf結合体の液体調製物 Expired - Fee Related JP5570988B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07115047 2007-08-27
EP07115047.8 2007-08-27
PCT/EP2008/061232 WO2009027437A1 (en) 2007-08-27 2008-08-27 Liquid formulation of g-csf conjugate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013229688A Division JP5836351B2 (ja) 2007-08-27 2013-11-05 G−csf結合体の液体調製物

Publications (3)

Publication Number Publication Date
JP2010536929A JP2010536929A (ja) 2010-12-02
JP2010536929A5 true JP2010536929A5 (enExample) 2011-04-21
JP5570988B2 JP5570988B2 (ja) 2014-08-13

Family

ID=39862881

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010522361A Expired - Fee Related JP5570988B2 (ja) 2007-08-27 2008-08-27 G−csf結合体の液体調製物
JP2013229688A Expired - Fee Related JP5836351B2 (ja) 2007-08-27 2013-11-05 G−csf結合体の液体調製物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013229688A Expired - Fee Related JP5836351B2 (ja) 2007-08-27 2013-11-05 G−csf結合体の液体調製物

Country Status (24)

Country Link
US (1) US8546328B2 (enExample)
EP (2) EP2197919B1 (enExample)
JP (2) JP5570988B2 (enExample)
KR (1) KR20100052501A (enExample)
CN (2) CN101827864A (enExample)
AU (1) AU2008292186B9 (enExample)
BR (1) BRPI0815975B8 (enExample)
CA (1) CA2696594C (enExample)
CY (1) CY1115908T1 (enExample)
DE (1) DE202008017456U1 (enExample)
DK (1) DK2197919T3 (enExample)
EA (1) EA020069B1 (enExample)
ES (1) ES2476915T3 (enExample)
HR (1) HRP20140590T1 (enExample)
IL (1) IL204190A (enExample)
MX (1) MX2010002448A (enExample)
NZ (1) NZ583276A (enExample)
PL (1) PL2197919T3 (enExample)
PT (1) PT2197919E (enExample)
RS (1) RS53404B (enExample)
SI (1) SI2197919T1 (enExample)
UA (1) UA98001C2 (enExample)
WO (1) WO2009027437A1 (enExample)
ZA (1) ZA201000798B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5657698B2 (ja) * 2010-01-19 2015-01-21 ハンミ サイエンス カンパニー リミテッドHanmi Scienceco.,Ltd. 持続型顆粒球コロニー刺激因子結合体の液剤
CN102892780B (zh) 2010-03-17 2015-07-29 通益制药有限公司 获得生物活性的重组人g-csf的方法
EP2384759A1 (en) 2010-05-06 2011-11-09 Suomen Punainen Risti Veripalvelu Sulphated hyaluronic acid in combination with G-CSF for use in mobilising blood stem cells
CN108368512B (zh) * 2016-04-18 2020-03-27 江苏恒瑞医药股份有限公司 一种重组人粒细胞集落刺激因子的制备方法
IT201700108526A1 (it) * 2017-09-28 2019-03-28 Alfasigma Spa Composizioni orali per il trattamento del refluso gastroesofageo.
EP3773468A2 (en) * 2018-05-04 2021-02-17 Ilkogen Ilaç Sanayi ve Ticaret A.S. Stable hybrid fc fusion g-csf formulation
CN114224853B (zh) * 2022-01-04 2022-09-23 山东新时代药业有限公司 聚乙二醇化重组人粒细胞刺激因子注射用冻干制剂
IL318702A (en) * 2022-08-19 2025-03-01 Evive Biotechnology Shanghai Ltd Compositions containing G-CSF and their uses

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479268A (en) 1973-07-05 1977-07-13 Beecham Group Ltd Pharmaceutical compositions
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
CH596313A5 (enExample) 1975-05-30 1978-03-15 Battelle Memorial Institute
US4414147A (en) 1981-04-17 1983-11-08 Massachusetts Institute Of Technology Methods of decreasing the hydrophobicity of fibroblast and other interferons
US5675941A (en) 1983-12-09 1997-10-14 Dykmans; Maximiliaan J. Method and apparatus for constructing prestressed structures utilizing a membrane and floating dome assembly
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3676670D1 (de) 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US6004548A (en) 1985-08-23 1999-12-21 Amgen, Inc. Analogs of pluripotent granulocyte colony-stimulating factor
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
EP0719860B1 (en) 1988-05-13 2009-12-16 Amgen Inc. Process for isolating and purifying G-CSF
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US6166183A (en) 1992-11-30 2000-12-26 Kirin-Amgen, Inc. Chemically-modified G-CSF
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
GB9107846D0 (en) 1990-04-30 1991-05-29 Ici Plc Polypeptides
DE4014750A1 (de) 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)
US5399345A (en) 1990-05-08 1995-03-21 Boehringer Mannheim, Gmbh Muteins of the granulocyte colony stimulating factor
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
EP0648239A4 (en) 1992-07-02 1995-09-27 Collagen Corp BIOCOMPATIBLE POLYMERIC CONJUGATES.
AU5098193A (en) 1992-09-01 1994-03-29 Berlex Laboratories, Inc. Glycolation of glycosylated macromolecules
AU7097094A (en) 1993-06-01 1994-12-20 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
US5874075A (en) 1993-10-06 1999-02-23 Amgen Inc. Stable protein: phospholipid compositions and methods
DK1090645T3 (da) 1994-02-08 2006-03-27 Amgen Inc Oral tilförsel af kemisk modificerede proteiner
NZ281329A (en) 1994-02-23 1997-07-27 Kyowa Hakko Kogyo Kk Platelet production promoting agents comprising modified human granulocyte colony stimulating factor
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP2000506119A (ja) 1996-02-15 2000-05-23 ノボ ノルディスク アクティーゼルスカブ ポリペプチドのコンジュゲーション
DE69823046T2 (de) 1997-01-16 2005-03-31 Neose Technologies, Inc. Praktische in vitro sialylierung von rekombinanten glykpproteinen
AU744085B2 (en) 1997-06-06 2002-02-14 Kyowa Hakko Kirin Co., Ltd. Chemically modified polypeptides
US6540672B1 (en) * 1998-12-09 2003-04-01 Novo Nordisk A/S Medical system and a method of controlling the system for use by a patient for medical self treatment
FR2796071B1 (fr) 1999-07-08 2001-09-07 Hoechst Marion Roussel Inc Procede de purification de facteur de stimulation de colonies de granulocytes
DE60139110D1 (de) 2000-01-10 2009-08-13 Maxygen Holdings Ltd G-csf konjugate
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
JP4683810B2 (ja) * 2000-02-29 2011-05-18 中外製薬株式会社 長期安定化製剤
NZ522320A (en) 2000-05-12 2007-03-30 Neose Technologies Inc In vitro modification of glycosylation patterns of recombinant glycopeptides
CZ304855B6 (cs) 2000-05-15 2014-12-10 F. Hoffmann-La Roche Ag Kapalná farmaceutická kompozice obsahující pegylovaný lidský erythropoetin, způsob její přípravy, léčivo pro léčení chorob korelujících s anemií při chronickém renálním selhání a zařízení s jejím obsahem
NZ522847A (en) 2000-05-16 2004-11-26 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
KR100396983B1 (ko) 2000-07-29 2003-09-02 이강춘 고반응성의 가지 달린 고분자 유도체 및 고분자와 단백질또는 펩타이드의 접합체
US20040038878A1 (en) 2000-08-04 2004-02-26 Masahiko Tanikawa Injectable protein formulations
EP1329224A4 (en) 2000-09-01 2004-04-14 Chugai Pharmaceutical Co Ltd PREPARATIONS OF STABILIZED SOLUTIONS OVER A LONG PERIOD OF TIME
ES2561985T3 (es) 2001-10-10 2016-03-01 Ratiopharm Gmbh Remodelación y glicoconjugación de anticuerpos
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
SI21102A (sl) 2001-12-19 2003-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za izolacijo biološko aktivnega granulocitne kolonije stimulirajočega dejavnika
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
SI21273A (sl) 2002-07-31 2004-02-29 LEK farmacevtska dru�ba d.d. Priprava inkluzijskih teles z visokim deležem pravilno zvitega prekurzorja heterolognega proteina
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
PL1660134T3 (pl) 2003-08-08 2011-05-31 Fresenius Kabi Deutschland Gmbh Koniugaty hydroksyalkiloskrobi i G-CSF
DE10348550A1 (de) * 2003-10-20 2005-06-16 Hexal Biotech Forschungsgmbh Stabile wässrige G-CSF-haltige Zusammensetzungen
WO2005042024A1 (en) 2003-11-04 2005-05-12 Lek Pharmaceuticals D.D. Stable pharmaceutical composition comprising granulocyte-colony stimulating factor
CN1897812B (zh) 2003-12-03 2011-08-17 生物种属学股份公司 糖聚乙二醇化的粒细胞集落刺激因子
JP5743368B2 (ja) * 2004-01-08 2015-07-01 ラショファーム ゲーエムベーハー ペプチドのo結合型グリコシル化
DE202005021885U1 (de) 2004-03-11 2011-03-03 Fresenius Kabi Deutschland Gmbh Hydroxyalkylstärke-Protein-Konjugate, durch reduktive Aminierung hergestellt
EP2279752A3 (en) 2004-03-11 2011-08-24 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and a protein, prepared by native chemical ligation
DE102004036909B4 (de) 2004-07-29 2007-04-05 Infineon Technologies Ag Halbleiterbasisbauteil mit Verdrahtungssubstrat und Zwischenverdrahtungsplatte für einen Halbleiterbauteilstapel sowie Verfahren zu deren Herstellung
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US20080171857A1 (en) 2005-03-17 2008-07-17 Uma Devi Komath Process for the Purification of Recombinant Granulocyte-Colony Stimulating Factor
AU2006254543A1 (en) 2005-06-01 2006-12-07 Maxygen Holdings Ltd. PEGylated G-CSF polypeptides and methods of producing same
EP1762250A1 (en) 2005-09-12 2007-03-14 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine
DE202006020194U1 (de) 2006-03-01 2007-12-06 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
ITMI20061624A1 (it) 2006-08-11 2008-02-12 Bioker Srl Mono-coniugati sito-specifici di g-csf
RS52845B (sr) 2007-04-03 2013-12-31 Biogenerix Ag Postupci tretmana korišćenjem glikopegiliranog g-csf
US8207112B2 (en) * 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate

Similar Documents

Publication Publication Date Title
JP2010536929A5 (enExample)
JP2009523455A5 (enExample)
EA200970581A1 (ru) Кристаллическое твёрдое основание разагилина
EA201170053A1 (ru) Способ получения и сушки твердого разагилина в форме основания
JP2011527560A5 (enExample)
EP2589392A3 (en) Process for stabilizing an adjuvant containing vaccine composition
MY152114A (en) Novel pyrazole-4-n-alkoxycarboxamides as microbiocides
JP2013500371A5 (enExample)
FR2934865B1 (fr) Copolyamide semi-aromatique et son procede de preparation
EP3279313A3 (en) Hyperblebbing shigella strains
TW200635938A (en) Fluorosurfactants
JP2010241791A5 (enExample)
JP2007320968A5 (enExample)
JP2006303436A5 (enExample)
JP2010211102A5 (enExample)
JP2009249685A5 (enExample)
JP2010196033A5 (enExample)
JP2010177089A5 (enExample)
JP2010243737A5 (enExample)
JP2011515327A5 (enExample)
EP2311794A3 (en) Polymorphs of bromfenac sodium and methods for preparing bromfenec sodium polymorphs
TR201109686T2 (tr) Olmesartan'ın Farmasötik Bileşimleri.
JP2009055850A5 (enExample)
JP2009532412A5 (enExample)
JP2012250569A5 (enExample)